S R Drugs Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 17-07-2024
- Paid Up Capital ₹ 2.40 Cr
as on 17-07-2024
- Company Age 42 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.30 Cr
as on 17-07-2024
- Satisfied Charges ₹ 3.17 Cr
as on 17-07-2024
- Revenue -3.40%
(FY 2023)
- Profit 147.85%
(FY 2023)
- Ebitda 152.80%
(FY 2023)
- Net Worth 9.75%
(FY 2023)
- Total Assets 1.21%
(FY 2023)
About S R Drugs
The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.40 Cr.
The company currently has active open charges totaling ₹3.00 M. The company has closed loans amounting to ₹3.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suraiya Tambe, Ruknuddin Tambe, and Altaf Tambe serve as directors at the Company.
- CIN/LLPIN
U24231MH1982PTC027442
- Company No.
027442
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 1982
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at S R Drugs?
Executive Team (1)
RT
Ruknuddin Tambe
Managing DirectorAppointment Date: 15-Jun-1982
Status: Current
Board Members(2)
Financial Performance and Corporate Structure Insights of S R Drugs.
S R Drugs Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.4% decrease. The company also saw a substantial improvement in profitability, with a 147.85% increase in profit. The company's net worth moved up by a moderate rise of 9.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S R Drugs?
In 2023, S R Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indian Oxalate Limited
Active
35 years 8 months Suraiya Tambe, Ruknuddin Tambe and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The State Ind. Investment Corp. Of Maharashtra Ltd. Creation Date: 21 Jul 1984 | ₹3.00 M | Open |
Bank Of India Creation Date: 06 Mar 1998 | ₹2.00 Cr | Satisfied |
Bank Of India Creation Date: 26 Aug 1997 | ₹5.50 M | Satisfied |
How Many Employees Work at S R Drugs?
Unlock and access historical data on people associated with S R Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S R Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S R Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
